Results 271 to 280 of about 107,649 (340)
Some of the next articles are maybe not open access.
Overcoming skin barriers through advanced transdermal drug delivery approaches.
Journal of Controlled Release, 2022Upon exhaustive research, the transdermal drug delivery system (TDDS) has appeared as a potential, well-accepted, and popular approach to a novel drug delivery system.
Vivek Phatale +5 more
semanticscholar +1 more source
Recent advances in polymeric transdermal drug delivery systems.
Journal of Controlled Release, 2021Transdermal delivery has proven to be one of the most favorable methods among novel drug delivery systems. Since drugs administered by transdermal delivery systems avoid the gastrointestinal tract, and thus avoid conversion by the liver, the likelihood ...
F. Sabbagh, B. Kim
semanticscholar +1 more source
Drugs of Today, 2007
Although older monoamine oxidase inhibitors (MAOIs) are effective in the treatment of depressive disorders, they are underutilized in clinical practice due to main concerns about interaction with tyramine-containing food, and side effects. Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called ...
Ashwin A, Patkar +2 more
openaire +2 more sources
Although older monoamine oxidase inhibitors (MAOIs) are effective in the treatment of depressive disorders, they are underutilized in clinical practice due to main concerns about interaction with tyramine-containing food, and side effects. Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called ...
Ashwin A, Patkar +2 more
openaire +2 more sources
Drugs, 2009
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T, Duggan, Monique P, Curran
openaire +2 more sources
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T, Duggan, Monique P, Curran
openaire +2 more sources
Drugs, 2009
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
A Review on Transdermal Drug Delivery Systems
International Journal of Science Architecture Technology and EnvironmentR ecently delivery of drugs through the skin is being a challenging area for research because of barrier properties exhibit by the outermost layer of skin stratum corneum. The transdermal drug delivery system has offers significant clinical benefits over
M. Choudhari
semanticscholar +1 more source
Drug Discovery Today, 2004
Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems.
Beverley J, Thomas, Barrie C, Finnin
openaire +2 more sources
Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems.
Beverley J, Thomas, Barrie C, Finnin
openaire +2 more sources
Recent Advances in Oral and Transdermal Protein Delivery Systems.
Angewandte Chemie, 2022Protein and peptide drugs are predominantly administered by injection to achieve high bioavailability, but this greatly compromises patient compliance. Oral and transdermal drug delivery with minimal invasiveness and high adherence represent attractive ...
Yinxian Yang +5 more
semanticscholar +1 more source
Expert Opinion on Drug Delivery, 2005
Iontophoresis is a technique used to enhance the transdermal delivery of compounds through the skin via the application of a small electric current. By the process of electromigration and electro-osmosis, iontophoresis increases the permeation of charged and neutral compounds, and offers the option for programmed drug delivery.
Priya, Batheja +5 more
openaire +2 more sources
Iontophoresis is a technique used to enhance the transdermal delivery of compounds through the skin via the application of a small electric current. By the process of electromigration and electro-osmosis, iontophoresis increases the permeation of charged and neutral compounds, and offers the option for programmed drug delivery.
Priya, Batheja +5 more
openaire +2 more sources
Seminars in Reproductive Medicine, 2001
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources